The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

Share Price Information for Alliance Pharma (APH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 33.10
Bid: 32.95
Ask: 33.25
Change: -1.85 (-5.29%)
Spread: 0.30 (0.91%)
Open: 33.50
High: 34.30
Low: 32.85
Prev. Close: 34.95
APH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Product Acquisition

15 Sep 2006 07:00

Alliance Pharma PLC15 September 2006 For immediate release 15 September 2006 ALLIANCE PHARMA PLC ("Alliance Pharma" or "the Company") Further expansion of dermatology portfolio Alliance Pharma plc (AIM: APH), a speciality pharmaceutical company, is pleasedto announce that it has acquired marketing rights in the UK and Ireland for thewoundcare treatment Permitabs(R), adding a further product to the Company'srapidly growing dermatology portfolio. Permitabs(R), which is used for the cleansing and deodorising of eczematouslesions and wounds, has annualised sales of £275,000. The product, whose saleshave been growing at more than 20 per cent a year, was acquired from Derma UKLtd for a one-off cash consideration of £800,000, financed through the Company'ssenior debt facility provided by the Bank of Scotland. Permitabs(R), which is included in the British National Formulary of recommendedproducts, is a tablet containing potassium permanganate and is made into asolution by nursing staff for the treatment of patients. The product will bemarketed by Alliance's specialist dermatology sales force, which has anincreasing number of prescription products to sell and cross sell todermatologists. John Dawson, Alliance Pharma's Chief Executive, commented: "This latestacquisition gives further depth to our dermatology franchise, which in arelatively short period of time has become a significant growth area for theCompany. We continue to seek and evaluate dermatology products to increasefurther the range of products marketed by our specialist dermatology salesforce." For further information: Alliance Pharma plc + 44 (0) 1249 466966John Dawson, Chief ExecutiveMaddy Scott, Finance Directorwww.alliancepharma.co.uk Buchanan Communications + 44 (0) 20 7466 5000Mark Court/Lisa Baderoon/Rebecca Dietrich Notes to editors About Alliance Pharma Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceuticalcompany based in Chippenham, Wiltshire, UK. The company has a strong trackrecord of acquiring the rights to established niche brands and owns, or shares,the rights to 34 branded pharmaceutical products and continues to exploreopportunities to expand the range. Alliance Pharma's products are prescribed in the treatment of a wide range ofconditions and include brands used in periodontitis (a serious gum disease), theprevention of heart disease, in Parkinson's disease, in nutrition, in nasalinfections, in the treatment of dermatological conditions and in childbirth.Alliance Pharma's sales are mainly prescription driven. Its products aredistributed to hospitals directly and to UK and International pharmaceuticalwholesalers which service both hospital and retail pharmacies with theirprescription requirements. Alliance Pharma is also developing Posidorm for sleep disorders and Isprelor forthe induction of labour. Alliance Pharma joined the AIM market of the London Stock Exchange in December2003 and trades under the symbol APH. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th May 20247:00 amRNSFurther Update on Preliminary Results
8th May 20247:00 amRNSManagement Update
26th Apr 20247:00 amRNSPreliminary Results Publication Date
22nd Apr 20247:00 amRNSFurther update on timing of preliminary results
5th Apr 20247:00 amRNSUpdate on Timing of Preliminary Results
2nd Apr 202411:12 amRNSTotal Voting Rights
4th Mar 20248:00 amRNSTotal Voting Rights
4th Mar 20247:00 amRNSNotification of Full Year Results
5th Feb 20247:00 amRNSNew Chair Appointment
29th Jan 20247:00 amRNSFull Year Trading Update
2nd Jan 202410:51 amRNSBlock Listing Six Monthly Return
1st Dec 202312:23 pmRNSTotal Voting Rights
9th Nov 202311:17 amRNSNotification of Major Holdings
7th Nov 20237:00 amRNSAppointment of Non-Executive Directors
1st Nov 202312:50 pmRNSTotal Voting Rights
16th Oct 20236:13 pmRNSDirector Dealings
12th Oct 20232:51 pmRNSNotification of Major Interest in Shares
5th Oct 20234:39 pmRNSGrant of Options to Directors
2nd Oct 20233:14 pmRNSTotal Voting Rights
26th Sep 20237:00 amRNSInterim Results
22nd Sep 20235:28 pmRNSNotification of Major Holdings
4th Sep 20231:19 pmRNSNotification of Major Holdings
30th Aug 20234:29 pmRNSNotification of Major Holdings
29th Aug 202311:32 amRNSNotification of Major Holdings
15th Aug 20231:55 pmRNSNotification of Major Holdings
10th Aug 20237:00 amRNSNotification of Half Year Results
20th Jul 20239:54 amRNSDirector Dealing
19th Jul 20237:00 amRNSDirector Dealings
18th Jul 20237:00 amRNSHalf Year Trading Update
3rd Jul 20233:05 pmRNSTotal Voting Rights
29th Jun 20237:00 amRNSBlock Listing Six Monthly Return
1st Jun 20235:16 pmRNSTotal Voting Rights
25th May 202312:44 pmRNSResult of AGM
25th May 20237:00 amRNSAGM Statement
3rd May 202312:25 pmRNSTotal Voting Rights
3rd May 202312:08 pmRNSNotification of Major Holdings
12th Apr 202310:00 amRNSAnnual Report and Notice of AGM
5th Apr 202311:00 amRNSNotification of Major Holdings
4th Apr 202310:46 amRNSNotification of Major Holdings
3rd Apr 202310:04 amRNSTotal Voting Rights
31st Mar 20233:00 pmRNSNotification of Major Holdings
29th Mar 20237:00 amRNSNotification of Major Holdings
21st Mar 20234:59 pmRNSNotification of Major Holdings
21st Mar 20237:00 amRNSPreliminary Results
14th Mar 20231:47 pmRNSNotification of Major Holdings
7th Mar 202312:51 pmRNSNotification of Major Holdings
23rd Feb 20237:00 amRNSNotification of Full Year Results
1st Feb 20237:00 amRNSAppointment of NED and SID
30th Jan 20235:18 pmRNSNotification of Major Holdings
17th Jan 20237:00 amRNSFull Year Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.